Skip to content
Biodatica
Start free

J. DAVID GLADSTONE INSTITUTES

SAN FRANCISCO, CA

Oncologygene editingGrant-only
Compare Sign in to watch

What changed

NIH R35 · $0.4M · Integrative Structural Biology in Viral RNA Synthesis Machinery

2mo agoNew grantMay 1, 2026Source filing (opens the source filing in a new tab)

Momentum

64no change

Momentum 64 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

15,245 pre-ticker oncology companies at Grant-only

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    R35 · $437k · non-dilutive

    May 1, 2026

    UNIVERSITY OF MINNESOTA · PI LIU, BIN · NIGMS · award ends Dec 31, 2030 · Integrative Structural Biology in Viral RNA Synthesis Machinery

    NIH RePORTER · NIH RePORTER 11259282 (opens the source filing in a new tab)

  2. Grant

    R01 · $657k · non-dilutive

    Apr 1, 2024

    UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIU, BIN · NCI · award ends Mar 31, 2029 · Develop novel bispecific antibody-drug conjugates against metastatic lethal prostate cancer across subtype

    NIH RePORTER · NIH RePORTER 11303292 (opens the source filing in a new tab)

  3. Grant

    R01 · $666k · non-dilutive

    Apr 4, 2023

    UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROYBAL, KOLE T · NCI · award ends Mar 31, 2028 · Combination antigen sensing engineered T cell for precise recognition and enhanced elimination of solid tumors

    NIH RePORTER · NIH RePORTER 11308329 (opens the source filing in a new tab)

  4. Grant

    R01 · $749k · non-dilutive

    Jan 1, 2023

    J. DAVID GLADSTONE INSTITUTES · PI MARSON, ALEXANDER · NCI · award ends Dec 31, 2027 · Decoding and reprogramming T cells through synthetic biology for cancer immunotherapy

    NIH RePORTER · NIH RePORTER 11258562 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources